TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2345836

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Design strategies
Number of subjects: 22071
Study: 6985881

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29696643

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clopidogrel and ritonavir combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 12
Study: 24828082

Group type: EXPERIMENTAL
Intervention: Universal, school-based intervention for depression
Number of subjects: 5633

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5633

Group type: EXPERIMENTAL
Intervention: Universal, school-based intervention for depression (intent-to-treat sample)
Number of subjects: 5633
Study: 22270733

Group type: EXPERIMENTAL
Intervention: Automatic position-adaptive stimulation (AdaptiveStim)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Manual programming adjustment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Position-adaptive stimulation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 79
Study: 21054860

Group type: EXPERIMENTAL
Intervention: LUCAS-2 mechanical compression device
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Manual chest compression (control)
Number of subjects: 4000
Study: 17991232

Group type: EXPERIMENTAL
Intervention: Robinson bristle brush with pumice/water slurry (RBP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Scalpel blade scraping (SBS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (cemental periodontal ligament preserved)
Number of subjects: 45
Study: 15863111

Group type: EXPERIMENTAL
Intervention: Statistical mechanics techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional posturographic measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hurst rescaled range analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stabilogram diffusion analysis
Number of subjects: 0
Study: 11920976

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CBT and antidepressant medication
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 10464889

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 7 days)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg three times daily for 7 days)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 327

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 327
Study: 7605757

Group type: COMPARATOR
Intervention: 10 mL 0.125% bupivacaine plain solution (group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 mL 0.125% bupivacaine with 75 micrograms clonidine (group B + C)
Number of subjects: 22
Study: 2194767

Group type: EXPERIMENTAL
Intervention: Nicotine gum (20 mg, up to 10 squares/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 7
Study: 7395237

Group type: EXPERIMENTAL
Intervention: 75 mg mesterolone per day for 8 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31548106

Group type: EXPERIMENTAL
Intervention: Inspire 8F (Sorin) oxygenator
Number of subjects: 25

Group type: COMPARATOR
Intervention: Affinity Fusion (Medtronic) oxygenator
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Arterial and oxygenator exhaust correlations
Number of subjects: 25
Study: 31164375

Group type: EXPERIMENTAL
Intervention: Real-time feedback
Number of subjects: 66

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rescue breaths
Number of subjects: 66
Study: 28699832

Group type: EXPERIMENTAL
Intervention: Placebo stimulant medication
Number of subjects: 166

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 166
Study: 25025936

Group type: EXPERIMENTAL
Intervention: Core training (3 times/wk for 12 weeks)
Number of subjects: 20
Study: 23649919

Group type: EXPERIMENTAL
Intervention: Endotracheal lidocaine (3 ml 4% lidocaine via LITA tube)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous remifentanil alone (control group)
Number of subjects: 60
Study: 21178763

Group type: EXPERIMENTAL
Intervention: 7.5% saline per 6% dextran 70 (hypertonic saline/dextran, HSD)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: 7.5% saline (hypertonic saline, HS)
Number of subjects: 853

Group type: COMPARATOR
Intervention: 0.9% saline (normal saline, NS)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Hypertonic fluids (HSD and HS)
Number of subjects: 853
Study: 19246317

Group type: EXPERIMENTAL
Intervention: Fentanyl injected within 2 s into the forearm veins (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl injected in 2 s through the dorsal foot veins or the great saphenous vein (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl injected in 15 s through the same route as in Group A (Group C)
Number of subjects: 75
Study: 17846070

Group type: EXPERIMENTAL
Intervention: Home exercise programme
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: In-hospital exercise under physiotherapist supervision
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 26
Study: 16469151

Group type: EXPERIMENTAL
Intervention: CHO drink (75 g glucose and 93 g Polyjoule, 2732 kJ, 653 kcal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat drink (88% fat, cream blended with milk, 2732 kJ, 653 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat drink
Number of subjects: 12
Study: 15243149

Group type: EXPERIMENTAL
Intervention: CEMRA using ECST method
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: CEMRA using NASCET method
Number of subjects: 167

Group type: COMPARATOR
Intervention: DSA (reference standard)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: CEMRA and DSA
Number of subjects: 167
Study: 10674507

Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isobaric lidocaine 2%
Number of subjects: 40
Study: 8739453

Group type: EXPERIMENTAL
Intervention: Allogeneic leukocyte immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1856429

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 6178282

Group type: EXPERIMENTAL
Intervention: Imipramine, 1 mg/kg per day, increased by 1 mg/kg every other day until suppression of ventricular premature complexes or maximum dose of 5 mg/kg per day.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Imipramine, 5 mg/kg per day.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Imipramine (parent compound).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Imipramine.
Number of subjects: 22
Study: 31295395

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (Procter & Gamble)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control dentifrice containing 0.243% sodium fluoride and 0.3% triclosan (Colgate‐Palmolive)
Number of subjects: 36
Study: 27862646

Group type: EXPERIMENTAL
Intervention: In-person and online LILAC intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: In-person attention-matched control
Number of subjects: 39
Study: 25997544

Group type: EXPERIMENTAL
Intervention: 80 mg febuxostat
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40 mg febuxostat
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation (80 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test formulation (40 mg)
Number of subjects: 30
Study: 25616350

Group type: EXPERIMENTAL
Intervention: Air cholangiogram
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dye cholangiogram
Number of subjects: 49
Study: 21776838

Group type: EXPERIMENTAL
Intervention: 200 ml of liquid culture of Neocallimastix sp. CF 17 (about 10(6) TFU/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Encapsulated culture of Neocallimastix sp. CF 17
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (200 ml of autoclaved culture)
Number of subjects: 18
Study: 19755186

Group type: EXPERIMENTAL
Intervention: Symptom management (SM) telehealth intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both groups (SM intervention and usual care)
Number of subjects: 232
Study: 17162194

Group type: EXPERIMENTAL
Intervention: multilevel botulinum toxin A and comprehensive rehabilitation
Number of subjects: 46
Study: 15638049

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (US examination)
Number of subjects: 13
Study: 11522112

Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterols (1.6 g/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-enriched control spread
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Plant sterol margarine in patients treated with fibrates
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Plant sterol margarine in patients not treated with fibrates
Number of subjects: 53
Study: 9684633

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets (IIBNs)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Nonusers of permethrin-impregnated bed nets (IIBNs)
Number of subjects: 862
Study: 8143448

Group type: EXPERIMENTAL
Intervention: Intensive application of Duraphat varnish (three applications during 1 week, once a year)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (one application at the annual check-up)
Number of subjects: 134
Study: 3258124

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31968642

Group type: EXPERIMENTAL
Intervention: Active video games (exergaming)
Number of subjects: 0
Study: 31182054

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity exercise group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control non-exercise group
Number of subjects: 180
Study: 26756502

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, 2 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (2 mL)
Number of subjects: 90
Study: 25885409

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low dose Iohexol (CILDI) at 0.5 mL/h for 12 h
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single bolus of Iohexol (SBI)
Number of subjects: 17
Study: 24218874

Group type: EXPERIMENTAL
Intervention: Barley flake (BF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oat meal (OM)
Number of subjects: 100
Study: 21836140

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no compression stockings)
Number of subjects: 12
Study: 18775538

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25131
Study: 17878117

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (stimulus control instructions, sleep restriction, and sleep education and hygiene)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single‐component control group (sleep education and hygiene)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single‐component control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 15475831

Group type: EXPERIMENTAL
Intervention: losartan (50 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: enalapril (20 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 12062537

Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (1.5‐6 mg bid) in poloxamer depot formulation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (2‐4 mg bid) in saline or as a depot formulation in cyclodextrin
Number of subjects: 170
Study: 10197945

Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional model of care
Number of subjects: 103
Study: 7594671

Group type: EXPERIMENTAL
Intervention: 3, 10, or 30 micrograms of OspA vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 doses of OspA vaccine
Number of subjects: 30
Study: 2150644

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5mg twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nifedipine retard 20mg twice daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 64
Study: 533222

Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg (A)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg and diazepam 5 mg (AD)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg and fentanyl 0.2 mg (AF)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg, diazepam 5 mg and fentanyl 0.2 mg (ADF)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Atropine (A) or Atropine and Diazepam (AD)
Number of subjects: 342
Study: 31843420

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (9-week protocol with 4 sessions before and 7 sessions after surgery)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 96
Study: 31428750

Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft without a collagen membrane (TG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bovine-derived xenograft with a collagen membrane (CG)
Number of subjects: 19
Study: 28338546

Group type: EXPERIMENTAL
Intervention: Riluzole (50-200 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 25889066

Group type: EXPERIMENTAL
Intervention: Concept map study
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Self-explanation
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Concept map completion
Number of subjects: 91
Study: 22983839

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: White light gastroscopy (WLG)
Number of subjects: 200
Study: 21353308

Group type: EXPERIMENTAL
Intervention: Reliable condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unreliable condition
Number of subjects: 0
Study: 19622188

Group type: EXPERIMENTAL
Intervention: Soya-based cheese (45.97 mg isoflavones) taken once a day for 10 days under Western diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chronic intake of soya-based cheese under Western diet
Number of subjects: 24
Study: 17194961

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ginkgo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 0
Study: 15112863

Group type: EXPERIMENTAL
Intervention: Desloratadine (10 mg/2 tablets)
Number of subjects: 8
Study: 11529630

Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 9332682

Group type: EXPERIMENTAL
Intervention: Surgery during the follicular phase (n = 358)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Surgery during the luteal phase (n = 675)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Surgery during the follicular phase for ER-negative primaries (n = 300)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Surgery during the luteal phase for ER-negative primaries (n = 300)
Number of subjects: 1033
Study: 8187784

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg orally twice a day for 7 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ceftriaxone (3 g parenterally per day for 7 days)
Number of subjects: 42
Study: 3959571

Group type: EXPERIMENTAL
Intervention: 20 micron nylon screen filter in the arterial line (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No filter used in the arterial line (Group 2)
Number of subjects: 100
Study: 30865001

Group type: COMPARATOR
Intervention: Intravenous dexamethasone 0.11 mg/kg (D1 group)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Co-administered intravenous dexamethasone 0.11 mg/kg and intravenous dexmedetomidine 1.0 μg/kg (D2 group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous 0.9% saline (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: D1 and D2 groups (both dexamethasone)
Number of subjects: 66
Study: 28082116

Group type: EXPERIMENTAL
Intervention: Scleroligation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Band ligation
Number of subjects: 120
Study: 25547035

Group type: EXPERIMENTAL
Intervention: Actigraphy monitoring
Number of subjects: 93
Study: 23962259

Group type: EXPERIMENTAL
Intervention: Early, home-based, personalized program
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 100
Study: 21423112

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19207621

Group type: EXPERIMENTAL
Intervention: ERASE-Stress intervention (ES) consisting of 12 classroom sessions lasting 90 minutes each, including psycho-educational material, skill training, and resiliency strategies.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Waiting-list control group (WL)
Number of subjects: 114
Study: 17941584

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A (BTX‐A) every 3 months to adductors, medial hamstrings, and psoas muscles
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation (Control Group B)
Number of subjects: 67
Study: 15799592

Group type: EXPERIMENTAL
Intervention: Telephone counseling and the quit line's stop‐smoking booklet, which included information on ingredients found in cigarettes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone counseling and the quit line's stop‐smoking booklet plus a basic brochure with a generic cover.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone counseling and the quit line's stop‐smoking booklet plus a brochure targeted to individual cigarette brand and type.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (regardless of brochure type).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Those who reported reading some or all of the brochure.
Number of subjects: 0
Study: 11717595

Group type: EXPERIMENTAL
Intervention: Individualized CVD treatments according to current guidelines
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 9164196

Group type: COMPARATOR
Intervention: Standard AC therapy (4 courses)
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Intensified therapy (same total dose in 2 courses)
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Intensified and increased therapy (total dose doubled)
Number of subjects: 2305
Study: 7904106

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vehicle ointment (placebo)
Number of subjects: 34
Study: 3552906

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg tid for two weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2713990

Group type: EXPERIMENTAL
Intervention: Nipple stimulation for 45 minutes three times a day for three days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 31169350

Group type: EXPERIMENTAL
Intervention: On-treatment AOBPM DBP range of 68.6-78.6 mm Hg
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Clinical composite endpoint
Number of subjects: 1470
Study: 28378342

Group type: EXPERIMENTAL
Intervention: Yoga (12 supervised weekly sessions of 90 min; n=39)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Yoga (n=39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Written self-care advice (n=38)
Number of subjects: 77
Study: 25465484

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (AR and Conventional)
Number of subjects: 20
Study: 23875821

Group type: EXPERIMENTAL
Intervention: Initial Intervention Group (IIG)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Delayed Intervention Group (DIG)
Number of subjects: 600
Study: 21561033

Group type: EXPERIMENTAL
Intervention: Transdermal matrix system (100 microg/h)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Transdermal reservoir system (100 microg/h)
Number of subjects: 74
Study: 19236443

Group type: EXPERIMENTAL
Intervention: RHIIP (6.5 mg, 187 IU, inhaled via Cyclohaler DPI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SCIns (10 IU subcutaneous)
Number of subjects: 30
Study: 16837888

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day (group B)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (group C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 68